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Abstract The possible occurrence of increased non-en-
zymatic glycosylation of serum insulin-like growth factor
binding protein-3 (IGFBP-3) in vivo and the changes that
would simultaneously occur in serum levels of IGFBP-3
and insulin-like growth factor-1 (IGF-I) were investigated.
We measured levels of IGF-I and IGFBP-3 and the degree
of glycation of total serum protein and IGFBP-3, in serum
samples obtained from patients with poorly controlled non-
insulin-dependent diabetes (type 2) and from age-matched
non-diabetic controls. Type 2 diabetic patients had signif-
icantly higher glycated serum protein (GlyP) levels. GlyP
significantly correlated with age in the control (r = 0.315,
P<0.05) but not in the type 2 diabetes group. Control and
diabetic subjects had comparable serum IGF-I levels and
in both groups IGF-I levels tended to decrease with age 
(r = –0.567, P<0.001 and r = –0.465, P<0.05 for control
and type 2 diabetic subjects, respectively). In the type 2 
diabetes group, IGF-I levels showed a negative correlation
with serum GlyP values (r = –0.476, P<0.05). Type 2 dia-
betic and control patients had comparable serum IGFBP-3
levels, which were significantly higher in diabetic patients
in the older age subgroups. A negative correlation was
found between IGFBP-3 levels and age in the control 
(r = –0.705, P<0.001) and in the type 2 diabetes groups 
(r = –0.463, P<0.05). A significant negative correlation
was found between IGFBP-3 levels and GlyP in control 
(r = –0.449, P<0.002) but not in type 2 diabetic subjects.
The mean glycated IGFBP-3 (GlyIGFBP-3) levels were
higher in the oldest type 2 diabetic patients. In these pa-
tients, GlyIGFBP-3 was negatively associated with IGF-I
levels (r = –0.447, P<0.05). The IGF-I/IGFBP-3 molar ra-
tio was significantly reduced in the 46–60-year-old type 2
diabetic group, whereas the IGF-I/IGFBP-3 ratio was pos-
itively and significantly correlated with GlyP levels only
in the control group (r = 0.489, P<0.01). Our results show
that: a) increased non-enzymatic glycosylation of IGFBP-
3 occurs in vivo; and b) this effect is accompanied by an
increase in IGFBP-3 levels. These results suggest that the
IGF-I/IGFBP-3 system is another target for the metabolic
derangements of type 2 diabetes. Its alterations might play
a role in diabetic complications.
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Introduction
Hyperglycaemia, a diagnostic feature of diabetes mellitus,
leads to increased formation and accumulation of non-en-
zymatic protein glycation products [1,2]. Non-enzymatic
glycation has been demonstrated to affect a number of pro-
teins with relatively long half-lives (months to years), pro-
teins with half-lives of days to weeks and in short-lived
proteins [3–5].
Insulin-like growth factors I and II (IGF-I and IGF-II)
are peptides which have been shown to have diverse mi-
togenic and metabolic effects [6–8]. IGF-I has been pos-
tulated to play an important role in the progression of di-
abetic vascular disease, retinopathy and nephropathy. In
plasma, IGFs circulate bound to a family of high affinity
binding proteins (IGFBPs) [9–11]. In postnatal life, the ma-
jor IGFBP is IGFBP-3, which is almost completely satu-
rated with IGFs [12]. IGF, IGFBP-3 and a unique acid-la-
bile subunit (ALS) form a ternary complex which seques-
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ters more than 75% of the total circulating IGFs, each com-
ponent depending directly or indirectly upon serum growth
hormone levels [13]. The IGF contained in the ternary com-
plex appears to be biologically inactive and only the free
IGF-I serum fraction (<5% of total serum IGF-I levels)
might be biologically active. Experimental evidence dem-
onstrates that IGFBPs not only function as IGF carriers but
also regulate their accessibility to cell-surface-specific re-
ceptors and their consequent bioactivity [13, 14].
We have previously reported that in untreated diabetic
rats there is an increase in the amount of 125I-IGF-I bound
to IGFBP-3 and that such an increase is related to the de-
gree of serum protein glycation [15]. We have further 
demonstrated that: (a) IGFBP-3 can be non-enzymatically
glycosylated in vitro; and (b) this process affects both
IGFBP-3 binding properties and IGFBP-3 modulatory ef-
fect upon the mitogenic action of IGF-I [16]. Thus, if
IGFBP-3 glycation occurs in vivo, the consecutive changes
induced in its biological properties could contribute to the
pathogenesis of growth defects and to the development of
some chronic complications observed in patients with
poorly controlled diabetes.
In order to test this hypothesis, we studied the levels of
IGF-I, IGFBP-3 and its degree of non-enzymatic glycosy-
lation as well as the total glycated protein. The study was
carried out in serum samples obtained both from a group
of control non-diabetic volunteers and from a group of type
2 diabetic patients with poor metabolic control.
Subjects and methods
Population sample
Twenty-three type 2 diabetic patients (9 men and 14 women; 35–70
years old; mean 57±2 years) were studied. The degree of glycaemic
control was assessed by measurement of fasting blood glucose 
(mean 14.4±0.72 mmol/l) and glycated protein (GlyP) levels. Ac-
cording to the body mass index (BMI = weight/height2), 48% of the
type 2 diabetic patients were obese (BMI above 27 and 25 for men
and women, respectively) [17]. Patients were treated with diet alone
or diet plus an oral hypoglycaemic agent (glibenclamide), and none
of them received insulin. The average duration of diabetes was
7.8±1.5 years (range 1–24 years). One patient had retinopathy and
clinical signs of neuropathic complications, while none of them had
clear signs of severe impairment of kidney function. Subjects in the
non-diabetic control group included 43 adult volunteers (12 men and
31 women) with a mean age of 46±2 years (range 20–70 years). In
this group, 37% were obese as assessed by BMI. They had normal
fasting blood glucose levels (mean 5.1±0.15 mmol/l) and no evidence
of diabetes, hypertension or any other hormonal or metabolic disease.
Involvement of human subjects in this project was approved by
the institutional review board at CENEXA, and written informed
consent was obtained from each subject prior to their involvement
in this study.
Assays
Blood samples were obtained by peripheral venipuncture without
anticoagulant, allowed to clot and then centrifuged; the serum ob-
tained was then kept frozen at –20°C until further use. Blood glu-
cose was measured with the glucose GOD-PAP kit kindly provided
by Boehringer Mannheim, Germany, Buenos Aires, Argentina.
Total glycosylated proteins. GlyP were measured after boronate-af-
finity chromatography, a method which relies on the affinity of the
cis-diol group in stable glycated proteins for boronate anion [18]. In
brief, 50 µl serum was applied to a pre-equilibrated 1 ml column con-
taining agarose-immobilized boronic acid at room temperature. Af-
ter 5 min, the “unbound”, non-glycated proteins were eluted with
10 ml of 250 mmol/l ammonium acetate buffer, pH 8.0. The remain-
ing “bound” glycated proteins were then eluted with 5 ml of the
100 mmol/l Tris buffer containing 200 mmol/l sorbitol, pH 8.5. Pro-
tein concentrations in each fraction were assayed using the method
of Bradford [19]. Aliquots of these samples were then concentrated
(10–20 fold concentration) using an Amicon-10 filter (Amicon, Bev-
erly, Mass., USA) and stored at –20°C for later use in the IGFBP-3
assay.
IGFBP-3 radioimmunoassay (RIA). IGFBP-3 levels were measured
using a commercial RIA kit (Diagnostic Systems Laboratories Inc.
Webster, Texas, USA). Serum samples were diluted 1 :100 and as-
sayed according to the manufacturer’s instructions which have shown
that the analytical sensitivity of this IGFBP-3 assay is 0.9 ng/ml and
that the inter- and intra-assay coefficients of variation (6 replicates
each) range from 5.3 to 6.7% and 4.2 to 8.2%, respectively. Parallel
curves were obtained using serial dilutions of either IGFBP-3 stan-
dard or human serum samples.
IGF-I assay. Total IGF-I levels were determined in the samples by
RIA after serum extraction by the acid-ethanol method [20]. For as-
say purposes, hrIGF-I (Bachem Inc., Torrance, Calif., USA) was used
as standard and tracer. The hormone was iodinated with 125I by means
of the chloramine-T method [21] at a specific activity of 400–450
µCi/µg and purified on a Sephadex G-50 column [22]. The rabbit
polyclonal antibody (UBK487), employed at 1 :10 000 dilution, was
a generous gift from Dr. L. E. Underwood (Division of Pediatric En-
docrinology, University of North Carolina at Chapel Hill, USA). The
intra- and inter-assay coefficients of variation were 10.9 and 13.0%,
respectively. Under our working conditions, serial dilutions of
rhIGF-I standard and extracted serum gave parallel displacement
curves.
The IGF-I/IGFBP-3 molar ratio was calculated considering an
estimated molecular weight of 7600 for IGF-I and 40 000 for 
IGFBP-3. This molar ratio has been extensively used in the past as
an indirect index of “free” IGF-I [23].
Statistical analysis
Results are expressed as mean±SEM. For data analysis, samples
were divided into 4 age groups: ≤29, 30–45, 46–60 and over 60 years.
Differences between groups were assessed by the Student’s t-test.
Due to the number of the groups a comparison between age-matched
controls and type 2 diabetic patients was feasible only in the 46–60
year and over 60 year groups. The correlation among different pa-
rameters was analysed using the Pearson’s correlation coefficient as
well as the linear and multiple regression method. RIA data were an-
alysed using the RIA Data Reduction Program for the IBM-PC [24].
Results
Table 1 shows the data for non-diabetic control and dia-
betic subjects grouped according to age. All diabetic pa-
tients had statistically significantly higher serum GlyP lev-
els than control subjects, data which coincided with the
high fasting glucose levels found in the former. The levels
of total glycated protein showed a positive and significant
correlation with the age of the subjects in the control 
(r = 0.315, P<0.05, n = 45) but not in the type 2 diabetes
group. We did not statistically compare control and type 2
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diabetic patients in the 30–45 year group due to the inad-
equate number of diabetic subjects.
Control and diabetic subjects had comparable serum
IGF-I levels both when the sample was considered as a
whole (138.4±11.8 vs 118.9±10.6 µg/l, respectively) and
after the subjects had been grouped by age (Table 1). 
IGF-I levels exhibited a trend of decreasing values with
the increase of age on both groups (r = –0.576, P<0.001
and r = –0.465, P<0.05 for control and type 2 diabetic sub-
jects, respectively).
In the type 2 diabetes group, the IGF-I levels showed a
negative correlation with serum GlyP values (r = –0.476,
P<0.05). There were no significant correlations between
IGF-I levels and duration of diabetes or BMI. 
Comparable serum IGFBP-3 levels were measured in
type 2 diabetic and control subjects (mean, 3.61±0.31 vs
3.16±0.20 mg/l, respectively). The mean values measured
in diabetic patients in the 46–60 and over 60 years sub-
groups were significantly higher than those in control sub-
jects (Table 1).
As shown in Fig. 1A, a negative correlation was found
between IGFBP-3 levels and the age of the subjects both
in the control (r = –0.705, P<0.001; Fig. 1A) and in the
type 2 diabetes groups (r = –0.463, P<0.05; Fig. 1B). Fur-
thermore, the strong trend of decreasing IGFBP-3 levels
with increasing GlyP present in the control group (r =
–0.449, P<0.002; y = 4.747–0.382 x) was not found in 
type 2 diabetic subjects (r = –0.299, P = 0.165; y = 4.713–
0.101 x).
In control subjects, a strong linear correlation was 
observed between IGFBP-3 and IGF-I levels (r = 0.511,
P<0.001; Fig 2A). This association was absent in the 
type 2 diabetic group (r = 0.267, P = 0.217; Fig. 2B).
In order to investigate the extent of IGFBP-3 glycation
in vivo, the total IGFBP-3 in serum was separated by af-
finity boronate chromatography as stated in Subjects 
and methods. In control subjects, the “bound” glycated
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Group (n) Age Gly Protein IGFBP-3 Gly IGFBP-3 IGF-I IGF-I/IGFBP-3
(years) (%) (mg/l) (%) (µg/l) (mol/mol)
Control (8) <29 3.6 ± 0.60 4.0 ± 0.36 3.6 ± 0.6 176 ± 23 0.22 ± 0.03
Control (14) 30–45 3.5 ± 0.21 4.4 ± 0.16 3.5 ± 0.5 154 ± 13 0.21 ± 0.02
Type 2 diabetes (3) 10.4 ± 2.30 3.2 ± 0.50 4.5 ± 3.2 133 ± 64 0.19 ± 0.08
Control (13) 46–60 3.3 ± 0.35 2.4 ± 0.20 2.9 ± 0.3 108 ± 7 0.25 ± 0.02
Type 2 diabetes (11) 10.0 ± 1.80 4.4 ± 0.49 3.9 ± 0.6 120 ± 11 0.16 ± 0.02
P<0.01 P<0.001 N.S. N.S. P<0.01
Control (8) >60 4.8 ± 0.78 1.9 ± 0.15 2.7 ± 0.3 97 ± 16 0.28 ± 0.06
Type 2 diabetes (9) 12.4 ± 0.90 3.0 ± 0.28 3.8 ± 0.4 108 ± 17 0.23 ± 0.04
P<0.001 P<0.01 P<0.05 N.S. N.S.
Data are means±SEM
Table 1 Parameters measured
in control and diabetic patients
Fig. 1 Correlation of IGFBP-3 levels with the age of control (A) 
(r = –0.705, P<0.001) and type 2 diabetic (B) (r = –0.463, P<0.05)
patients. Regression curve equations: y = 5.795 – 0.0578 x and y =
6.237– 0.047 x, for control and type 2 diabetic patients, respectively
IGFBP-3 fraction had a mean value of 3.1±0.21%, being
slightly though not significantly higher in type 2 diabetic
patients (4.18±0.65%). When the subjects were grouped
by age, the mean GlyIGFBP-3 levels showed a trend to in-
crease in type 2 diabetic patients, but the difference only
attained statistical significance in the oldest subgroup 
(Table 1).
No correlation was found between GlyIGFBP-3 levels
and age of the subjects (r = –0.204, P = 0.179 and r =–0.324,
P = 0.131 for control and type 2 diabetes, respectively) or
GlyP levels (r = 0.002, P = 0.861 and r = 0.176, P = 0.421
for control and type 2 subjects) in either group. In diabetic
patients, the glycated IGFBP-3 fraction was negatively as-
sociated with IGF-I levels (r = –0.447, P<0.05).
The IGF-I/IGFBP-3 ratio had comparable mean values
in the control and in the type 2 diabetic groups (0.24±0.01
and 0.19±0.02, respectively). When the subjects were
grouped by age, the mean ratio was significantly reduced
only in the 46–60 year type 2 diabetic subgroup (Table 1
and Fig. 3). The IGF-I/IGFBP-3 ratio was not related to
age, but it was significantly related to GlyP levels only in
the control group (r = 0.489, P<0.01).
Discussion
As expected, there was an increase in the degree of non-
enzymatic glycosylation of serum protein in patients with
poorly controlled type 2 diabetes. The IGFBP-3 glycated
fraction was also larger in these patients, but the difference
only attained statistical significance in patients older than
60 years (Table 1). Thus, the increased protein glycation
which occurs in patients with sustained hyperglycaemia
also affects IGFBP-3, a process that is apparently more
marked in older patients.
In addition, the IGFBP-3 levels were higher while the
IGF-I/IGFBP-3 ratio was lower in the 46 to 60-year-old
type 2 diabetic than in the corresponding control subjects.
Serum IGF-I and IGFBP-3 levels are strongly influenced
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Fig. 2 Correlation between IGF-I and IGFBP-3 levels in control (A)
(r = 0.511, P<0.001) and type 2 diabetic (B) (r = 0.267, P = 0.217)
patients. Regression curve equations: y = 42.61+30.33 x and y =
86.46+8.998 x, for control and type 2 diabetic patients, respectively
Fig. 3 IGF-I/IGFBP-3 ratio in non-diabetic control and type 2 
diabetic patients grouped by age. Data represent mean±SEM. The
number of cases is shown in Table 1
by age [25–27]; thus, this variable should be taken into
consideration in a statistical evaluation of the changes ob-
served in these two parameters in both experimental
groups.
The levels of IGF-I and IGFBP-3 showed a trend to de-
crease as a function of age in the control group. This age-
dependence of serum IGF-I levels has been previously re-
ported in the literature [28–30]. Conflicting results, how-
ever, have been published regarding IGF-I levels in diabetic
patients, namely, decreased [25,31,32], increased in type 1
but normal in type 2 [33] or even unchanged [34, 35]. Our
data would suggest that in type 2 diabetic and in control
subjects IGF-I levels undergo a similar age-dependent vari-
ation with no significant changes in their absolute values
when the comparison is done between groups paired by age.
IGFBP-3 levels decreased as a function of age in type
2 diabetic patients and in the control group (Fig. 1) as has
been previously reported in this latter group [23, 27, 36],
Bang et al. [37] have recently reported that basal im-
munoreactive IGFBP-3 levels in type 2 diabetic patients
do not differ from those measured in healthy obese and
non-obese subjects. The discrepancy between our data and
theirs may only be apparent and ascribed to differences in
the respective protocols. In the previous study [37], only
six type 2 diabetic patients with heterogeneous degrees of
metabolic control were included; different types of treat-
ment were used, and results were not compared against
proper age-matched controls. In fact, the diabetic patients
were older than the controls. Conversely, we employed a
larger population of diabetic patients, all of them uncom-
pensated and without insulin treatment (Table 1), and com-
parisons were done with control patients grouped by age.
We do not find a clear explanation for the IGFBP-3 in-
crease. Excess growth hormone secretion does not seem to
be implicated, since a concomitant IGF-I increase would
be expected. The patients had neither clinically evident re-
nal failure nor were under glucocorticoid treatments (both
being known to increase IGFBP-3 levels) [26]. Other pos-
sible causes are changes in the IGFBP-3 half-life or in its
proteolitic activities.
In our control group, the levels of GlyP increased as a
function of the age of the subjects, but this relation was ab-
sent in the diabetic group. This fact would suggest that the
increased non-enzymatic glycosylation of serum proteins
observed in poorly controlled diabetic patients does not de-
pend on their chronological age.
A negative correlation was found between GlyP and
IGFBP-3 levels in the control group; thus, in diabetic pa-
tients we might expect to find lower IGFBP-3 levels than
in control patients. Since we found the opposite, we could
assume that in type 2 diabetic patients the normal relation-
ship between GlyP and IGFBP-3 levels was broken and re-
placed by another which superseded such control.
The IGF-I/IGFBP-3 ratio gives an estimation of the free
IGF-I fraction and its bioactivity [23]. This ratio was lower
– though only significantly different in the 46–60 age group
in diabetic patients. We also found a statistically signifi-
cant increase in the glycated IGFBP-3 as a percentage of
total serum IGFBP-3 in type 2 diabetic patients over 60
years old. However, in contrast with other serum proteins
[4] this was a small increment probably due to the short
half-life of the IGFBP-3 [9].
In brief, our results show that: (a) the non-enzymatic
glycation of IGFBP-3 occurs in vivo, as shown in poorly
controlled diabetic patients; (b) this effect is accompanied
by an increase in the serum levels of IGFBP-3; (c) a de-
crease in the IGF-I/IGFBP-3 ratio in the 46–60 year group,
possibly indicating a reduction in the free IGF-I fraction.
Altogether, these results suggest that the IGF-I/IGFBP-3
system is another target for the metabolic derangements of
type 2 diabetes. Its alterations might play a role in diabetic
complications.
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